Navigation Links
FDA Accepts to File Cell Therapeutics' New Drug Application for Pixantrone
Date:8/23/2009

SEATTLE, Aug. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.

"The FDA's acceptance to file our pixantrone NDA represents a significant milestone for CTI and for patients with relapsed and refractory aggressive NHL. We look forward to working with the FDA and their final decision on our request for priority review," noted James Bianco, M.D., Chief Executive Officer of CTI.

About Pixantrone

Pixantrone (BBR 2778), is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from currently marketed anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although anthracyclines are sufficiently effective to be used as first-line (initial) treatment, anthracyclines cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if the patient's disease returns. Pixantrone also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class. The FDA is required to set an action date for review of an application 74 days after the initial submission of the NDA. CTI expects to receive the action date for this drug candidate from the FDA and a
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. FDA Accepts Drug Application for Miconazole Lauriad(R) to Treat Oropharyngeal Candidiasis
2. Erik Estrada Accepts Honorary Appointment from Project Lifesaver International
3. House Energy & Commerce Committee Accepts Independence at Home Pilot Program as Amendment During Health Bill Markup
4. FDA Accepts Tris Pharmas ANDA with Paragraph IV Certification for a Generic Equivalent to Delsym
5. Victory Pharma, Inc. Announces FDA Accepts MGX006 NDA for Review
6. Specialty Hospitals of America Accepts First Patients in New Long Term Critical Care Hospital Located in South East Washington
7. FDA Accepts Final Section of NDA Filing for LUCASSIN(R)
8. NYSE Amex Accepts China Shenghuos Compliance Plan for Continued Listing
9. NYSE Amex LLC Accepts Plan of Compliance of The Quantum Group, Inc.
10. United States Patent and Trademark Office Accepts CoolTouch's Re-examination Request for Cynosure '873 Patent
11. NYSE Amex Accepts Interleukin Genetics Plan to Meet Continued Listing Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... The Wehrman Collaborative, LLC (WeCo) ... disabled users by disabled users, has granted use ... Educational Resources of Burnsville, Minnesota, for their ... the Minnesota Alliance for Patient Safety of Minneapolis, ... website. Both organizations have met WeCo’s Standards ...
(Date:10/25/2014)... Everett, WA (PRWEB) October 25, 2014 ... their insulation has ‘gone bad’ need wonder no more. ... that homeowners should watch out for when it ... Bad insulation, according to the article released by Clean ... emphasize for homeowners that any insulation that has deteriorated, ...
(Date:10/25/2014)... Lyme, CT (PRWEB) October 25, 2014 ... an upcoming episode of Innovations with Ed Begley Jr, ... show times TBA. , In this episode, Innovations will ... solution helping to protect fragile, thinning skin on arms, ... Viewers will learn about these versatile products, which help ...
(Date:10/25/2014)... -- Not getting the right amount of sleep might ... suggests. Those who sleep less or more than ... be more prone to developing the chronic condition, which ... authors concluded that duration and quality of sleep are ... bowel diseases. "Both short and long durations of ...
(Date:10/25/2014)... Current osteoporosis screening guidelines and tools fail to ... osteoporosis-related fractures, a new study says. "If ... that help us accurately predict who will suffer ... these at-risk people for preventive measures," study author ... division of general internal medicine and health services ...
Breaking Medicine News(10 mins):Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2
... Free ... Burrill & Co., BioAnalytics Group, ChanTest, GE Healthcare, Profectus Biosciences, Protagen, UNiConnect, and More ... Boston, MA ... online events for the healthcare, education and energy markets, and LabRoots , a ...
... Health Spending to Reach $1,318 per Person by 2018 ... report released today based on research by Emory ... Partnership to Fight Chronic Disease (PFCD), shows increasing obesity rates in ... care spending for states and individuals. The study, which was commissioned ...
... finds adults with records were more likely as tots to not ... are fearless at 3 years of age might just be poised ... poor fear conditioning at the tender age of 3 can ... other factors, such as education of the parents, large family size, ...
... ... Call Center , ... (PRWEB) November 17, 2009 -- VoiceNation, a leader in voicemail and ... powerful Customer Relationship software package. TASterix was chosen for its reliability, scalability and ...
... Richard ... civil damages award known in Berks County. The personal injury lawyer represented a ... Jurewicz negotiated with the Austrian manufacturer of the machine and won a settlement in ... ...
... ... manufacturer of support surface products for medical applications, introduces the ROHO Hybrid Elite cushion. ... DRY FLOATATION® with the stability of a Jay® contoured foam base engineered specifically for ... Belleville, ...
Cached Medicine News:Health News:BioConference Live Kicks-off Three Day Online Event for Life Science and Biotech Communities Today at 9:00 AM Eastern 2Health News:BioConference Live Kicks-off Three Day Online Event for Life Science and Biotech Communities Today at 9:00 AM Eastern 3Health News:Obesity Rates Will Continue to Increase, Drive Health Care Costs in New Jersey in Next Decade, According to New Study 2Health News:'Fearless' 3-Year-Olds Might Be Tomorrow's Criminals 2Health News:'Fearless' 3-Year-Olds Might Be Tomorrow's Criminals 3Health News:VoiceNation Calls on TASterix as Their CRM Solution 2Health News:Galfand Berger Personal Injury Lawyer Richard Jurewicz Obtains Record Recovery In Berks County 2Health News:The ROHO Group Introduces ROHO Hybrid Elite™ Two Trusted Brands; One Effective Cushion 2
(Date:10/25/2014)... -- Burzynski Research Institute, Inc. (BRI) announced today that ... the company permission to conduct an open-label study of ... of age with a diffuse intrinsic brainstem glioma (DIPG). ... treatment groups based on their age and whether or ... primary study endpoint is a decrease in the size ...
(Date:10/22/2014)... , Oct. 22, 2014  Medical ... laboratory which specializes in high complexity, state-of-the-art, ... is now offering new Cystic Fibrosis Testing ... generation DNA sequencing platforms. Cystic ... inherited multisystem disorder that affects the respiratory, ...
(Date:10/22/2014)... MADISON, N.J. , Oct. 22, 2014  Quest ... provider of diagnostic information services, today announced that its ... Ph.D., to serve as a director, effective December 1, 2014. ... Dr. Leiden is the Chairman, President and CEO ... 20 years of scientific and commercial experience in the ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Medical Diagnostic Laboratories, L.L.C. Institute for Biomarker Research Announces New Prenatal Cystic Fibrosis Tests 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: